PMID- 17295237
OWN - NLM
STAT- MEDLINE
DCOM- 20070823
LR  - 20220223
IS  - 0899-1987 (Print)
IS  - 0899-1987 (Linking)
VI  - 46
IP  - 7
DP  - 2007 Jul
TI  - Aneuploidy of chromosome Y in prostate tumors and seminal vesicles: a possible 
      sign of aging rather than an indicator of carcinogenesis?
PG  - 543-52
AB  - Chromosome Y aneuploidies have been reported as one of the recurrent cytogenetic 
      findings in prostate cancer (PCa) and many other solid and hematological tumors. 
      We have studied this aneuploidy in 28 patients with PCa undergoing radical 
      prostatectomy, one patient with benign hyperplasia (BPH) and four organ donors. A 
      total of 72 samples have been studied: 17 tumors, 25 nontumor prostate tissues, 1 
      BPH, 21 seminal vesicles samples obtained along with the prostate when patients 
      underwent radical prostatectomy and prostate tissues and seminal vesicles from 
      four organ donors. We have also studied the aneuploidy of chromosome Y in 
      peripheral blood from four of the patients and in seminal vesicles of 11 
      individuals with bladder cancer (BC). The study has been performed by 
      Fluorescence in situ hybridization (FISH) in uncultured cells. Our results 
      indicate that complete loss of chromosome Y is found in almost all the seminal 
      vesicles both from patients with PCa and patients with BC (samples obtained from 
      the tissue bank), and is more frequent in prostate tumors than in nontumor 
      samples. The percentages of chromosome Y loss in the tissues analyzed are 
      significatively higher than expected in lymphocytes considering the patient's age 
      as reported in the literature. The high percentage of chromosome Y loss found in 
      the nonmalignant seminal vesicles of these patients may be an indicator of an 
      ageing process rather than a primary cytogenetic alteration in the carcinogenesis 
      of the prostate. However, a contribution of this loss to chromosomal instability 
      and therefore, to the multistep tumorigenic process, cannot be discarded.
CI  - (c) 2007 Wiley-Liss, Inc.
FAU - Nadal, Marga
AU  - Nadal M
AD  - Centre de Genetica Medica i Molecular, IDIBELL-Institut de Recerca Oncologica, 
      Hospitalet de Llobregat, Gran Via s/n, 08907 Barcelona, Spain.
FAU - Pera, Guillem
AU  - Pera G
FAU - Pujadas, Jaume
AU  - Pujadas J
FAU - Abril, Jesus
AU  - Abril J
FAU - Gonzalez, Laura
AU  - Gonzalez L
FAU - Aguilo, Fernando
AU  - Aguilo F
FAU - Condom, Enric
AU  - Condom E
FAU - Gomez-Zaera, Montserrat
AU  - Gomez-Zaera M
FAU - Nunes, Virginia
AU  - Nunes V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Mol Carcinog
JT  - Molecular carcinogenesis
JID - 8811105
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aging/*pathology
MH  - *Aneuploidy
MH  - Cell Transformation, Neoplastic
MH  - Chromosomes, Human, Y/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Prostate/pathology
MH  - Prostatic Hyperplasia/*genetics/pathology
MH  - Prostatic Neoplasms/*genetics/pathology
MH  - Seminal Vesicles/*pathology
EDAT- 2007/02/14 09:00
MHDA- 2007/08/24 09:00
CRDT- 2007/02/14 09:00
PHST- 2007/02/14 09:00 [pubmed]
PHST- 2007/08/24 09:00 [medline]
PHST- 2007/02/14 09:00 [entrez]
AID - 10.1002/mc.20301 [doi]
PST - ppublish
SO  - Mol Carcinog. 2007 Jul;46(7):543-52. doi: 10.1002/mc.20301.